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A B S T R A C T
CDP diacylglycerol synthase (CDS) catalyses the conversion of phosphatidic acid (PA) to CDP-diacylglycerol, an
essential intermediate in the synthesis of phosphatidylglycerol, cardiolipin and phosphatidylinositol (PI). CDS
activity has been identiﬁed in mitochondria and endoplasmic reticulum of mammalian cells apparently encoded
by two highly-related genes, CDS1 and CDS2. Cardiolipin is exclusively synthesised in mitochondria and recent
studies in cardiomyocytes suggest that the peroxisome proliferator-activated receptor γ coactivator 1 (PGC-1α
and β) serve as transcriptional regulators of mitochondrial biogenesis and up-regulate the transcription of the
CDS1 gene. Here we have examined whether CDS1 is responsible for the mitochondrial CDS activity. We report
that diﬀerentiation of H9c2 cells with retinoic acid towards cardiomyocytes is accompanied by increased ex-
pression of mitochondrial proteins, oxygen consumption, and expression of the PA/PI binding protein, PITPNC1,
and CDS1 immunoreactivity. Both CDS1 immunoreactivity and CDS activity were found in mitochondria of H9c2
cells as well as in rat heart, liver and brain mitochondria. However, the CDS1 immunoreactivity was traced to a
peripheral p55 cross-reactive mitochondrial protein and the mitochondrial CDS activity was due to a peripheral
mitochondrial protein, TAMM41, not an integral membrane protein as expected for CDS1. TAMM41 is the
mammalian equivalent of the recently identiﬁed yeast protein, Tam41. Knockdown of TAMM41 resulted in
decreased mitochondrial CDS activity, decreased cardiolipin levels and a decrease in oxygen consumption. We
conclude that the CDS activity present in mitochondria is mainly due to TAMM41, which is required for normal
mitochondrial function.
1. Introduction
The heart has the highest levels of cardiolipin; it comprises as much
as 15–20% of the entire phospholipid phosphorus mass of that organ
[1]. This reﬂects the high mitochondrial density, and in cardiomyocytes
there are several thousand mitochondria that are arranged in a regular
pattern. Mitochondria are located around the nucleus, between the
myoﬁbrils and beneath the sarcolemma, and occupy nearly a third of
the volume of a cardiomyocyte [2,3]. The transcriptional regulators,
PGC-1α and β have been shown to serve as master regulators of mi-
tochondrial biogenesis and function [4,5] and in mice, combined
deﬁciency of both revealed cardiolipin deﬁciency [6]. This phenotype
was correlated with PGC-1α-mediated transcriptional control of CDP-
diacylglycerol synthase 1 (CDS1), an enzyme that catalyses the con-
version of PA to CDP-DG, an essential intermediate step in the bio-
synthesis of cardiolipin and phosphatidylinositol. Gene expression
proﬁling of PGC-1α/β−/− hearts revealed reduced expression of CDS1.
Moreover, CDS1 gene promoter-reporter co-transfection experiments
and chromatin precipitation studies demonstrated that PGC-1α co-
regulates estrogen-related receptors to activate the transcription of the
CDS1 gene [6]. In mammals, two homologous genes of CDS (CDS1 and
CDS2) have been cloned that are 73% identical and 92% similar [7–9].
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Human CDS1 is 461 amino acids long and has a calculated molecular
weight of ~53 kDa whilst CDS2 is 444 amino acids with a calculated
molecular weight of ~51 kDa. CDS genes homologous to mammalian
Cds are found in E. coli, S. cerevisiae, Drosophila, zebraﬁsh, plants and
cyanobacteria [9–16]. The structure of Cds from the bacterium, Ther-
motoga maritama (TmCdsA) indicates a homodimer and each monomer
contains nine transmembrane helices arranged into a novel fold with
three domains [17] (see Fig. 5B). An unusual funnel-shaped cavity
penetrates half way into the membrane, allowing the enzyme to si-
multaneously accept CTP and PA.
In mammalian cells, over-expressed CDS1 and CDS2 localise at the
endoplasmic reticulum (ER) [7,18,19]. Yet, previous studies in rat liver
and lung have indicated the presence of mitochondrial as well as mi-
crosomal CDS activity [20–23]. Moreover, expression studies indicate
that CDS1 and CDS2 exhibit quite diﬀerent tissue speciﬁcity [7]. In the
mouse, CDS2 appears to be ubiquitously expressed whilst CDS1 has a
restricted pattern of expression. CDS1 has been shown to be highly
expressed in the heart [24] and in SHHF (spontaneously hypertensive
heart failure) rats, an increase in CDS1 mRNA was observed with in-
creasing age whilst CDS2 mRNA decreased during heart failure devel-
opment [25]. The increase in CDS1 mRNA corresponded to an increase
in mitochondrial CDS activity with no change in microsomal CDS ac-
tivity [25].
In yeast, a single Cds protein, Cds1, has been characterised which is
localised exclusively at the ER [26,27]. A recent study in S. cerevisiae
has identiﬁed that Tam41 (Translocator maintenance protein), a mi-
tochondrial inner membrane peripheral protein functions as a CDP-DG
synthase for the synthesis of cardiolipin [26]. TAM41 was ﬁrst identi-
ﬁed for its role in maintaining the integrity and activity of the protein
import complexes, TIM23 and TIM22 [28]. However, in the absence of
Tam41, some cardiolipin was produced indicating that yeast Cds1 could
supply CDP-DG for cardiolipin synthesis. The aim of the present work
was to identify whether CDS1 was responsible for the CDS activity
found in mitochondria of mammalian cells including the heart. Our
recent studies have identiﬁed a lipid transporter, PITPNC1, to be en-
riched in the heart [29,30]. PITPNC1 is a PA/PI binding protein [31]
and could therefore supply PA for CDP-DG synthesis. In this study, we
have used an in vitro H9c2 cell model along with mitochondria from rat
heart, liver and brain to demonstrate that the mitochondrial CDS ac-
tivity is due to a peripheral protein, TAMM41, a mammalian homo-
logue of the recently-identiﬁed yeast Tam41 [26].
2. Material and methods
2.1. Materials
The following antibodies were purchased from Santa Cruz
Biotechnology: cytochrome c (6H2): sc-13561 mouse monoclonal,
Troponin I (H-170): sc-15368 rabbit polyclonal and anti-Myc antibody
9E10: sc-40 mouse monoclonal. The CDS1 antibody (CDP-diacylgly-
cerol synthase 1, mouse monoclonal) was purchased from either Abcam
(ab88121) or Novus Biologicals (Clone 2D10) as the same antibody is
sold by both companies. COXIV, rabbit polyclonal (#4844) was pur-
chased from Cell Signalling Technology; GRP75 (mortalin) Clone
N52A/42 mouse monoclonal was obtained from BioLegend; Calnexin
rabbit polyclonal was obtained from Enzo Life Sciences (ADI-SPA-865).
The antibody to PITPNC1 (RdgBβ), aﬃnity-puriﬁed rabbit polyclonal
antibody (Rb59) was a gift from Nils Halberg (Tavazoie lab),
Rockefeller University [32]. The peptide used to generate the antibody
was DPEKKATLNLPGMHSSDK (308–325a.a.) and therefore only re-
cognises the long form, splice variant 1 [30]. The antibody was char-
acterised further; it recognised recombinant protein and over-expressed
protein and ﬁnally knockdown of PITPNC1 by siRNA led to loss of the
appropriate band on the gel. Antibodies to PITPα (PAb:674) and PITPβ
(MAb:4A7) were made in-house and PAb:674 has been described pre-
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ATLAS antibodies. In Table 1, we provide a summary of the antibodies
used in this paper and whether the antibody has been validated for
western blotting. In many cases there are signiﬁcant number of pub-
lications where the antibody has been used as a marker for an organelle
or as a loading control but no formal validation has been done to our
knowledge. siRNA for rat CDS1_1 (Cat. No. SI01497811) rat CDS1_3
(Cat. No. SI01497825); rat CDS2_1 (Cat. No. SI01497839) and rat
CDS2_3 (Cat. No. SI01497853) and rat TAMM41_1 (Cat. No.
SI02905798) and rat TAMM41_2 (Cat. No. SI02905805), negative
control siRNA (Cat No. 1027310) were obtained from Qiagen.
2.2. H9c2 cell culture and diﬀerentiation and transfection of H9c2 cells
with siRNA
H9c2 cells (ATCC number CRL-1446) derived from embryonic BD1X
rat ventricular tissue were purchased from ATCC. The cells were cul-
tured in Dulbecco's modiﬁed Eagle's medium (DMEM) 1X w/GlutaMAX
+ Glucose + NaPyr. (Cat. No. 31966-021) supplemented with 10%
heat inactivated fetal calf serum (FCS) and 0.5 iu·mL−1 penicillin and
50 μg·mL−1 streptomycin at 37 °C with 10% CO2. Before 70% con-
ﬂuence, cells were split and seeded at 1.1 × 106 cells in T175 ﬂask
(175 cm2).
For diﬀerentiation, 5 × 105 cells were plated in 10 cm dishes with
10% FCS culture medium and cultured for 2 days. Once 80% conﬂuency
was reached, cells were cultured in medium with 1% FCS and daily
addition of 1 μM all-trans-retinoic Acid (Sigma). The culture medium
was replaced every 2 days for a total of 8–12 days.
Proliferating H9c2 cells were seeded in 2 × T175 ﬂasks (106 cells
per ﬂask) and transfected with a mixture of two siRNA (10 nM total)
with HiPerFect Transfection Reagent following the manufacturer in-
structions (Qiagen). Cells were incubated for 72 h to achieve conﬂuency
(~8 × 106 cells) prior to be used for experiments [34].
2.3. Immunoﬂuorescence protocol
H9c2 cells were grown on glass coverslips (19 mm, thickness 0) for
72 h. Cells were washed in phosphate-buﬀered saline (PBS) and sub-
sequently ﬁxed with 4% paraformaldehyde in PBS, pH 7.4 with
100 mM MgCl2 and 100 mM CaCl2 for 15 min at room temperature.
Following a further two washes in PBS, cells were permeabilised with
PBS containing 0.2% Triton X-100 and 100 mM glycine for 10 min at
room temperature. Cells were then washed again three times, before
blocking with 0.1% BSA in PBS with 100 mM glycine, for 30 min at
room temperature. In order to stain for nuclei and actin, 49,6-diami-
dino-2-phenylindole (DAPI) (400 μg/ml) and Rhodamine-phalloidin
(2 nM) was added for 30 min at room temperature in the dark.
Following incubation with the chemical stains, cells were washed three
times with blocking solution, three times with PBS, and ﬁnally rinsed
with d.H2O before mounting on a microscope slide with Fluoroshield
(Sigma, F6182).
2.4. COS-7 cells culture and transfection using FuGene HD
The plasmids pcDNA3.1-Myc-CDS1 and pcDNA3.1-Myc-CDS2 was
provided by Dr Tamas Balla (NICHD Bethesda, MD, USA) [18]. COS-7
cells were maintained in DMEM supplemented with 10% FCS and 0.5
iu·mL−1 penicillin and 50 μg·mL−1 streptomycin at 37 °C with 5% CO2.
COS-7 cells were transfected with FuGENE HD (Promega) as per man-
ufacturer's protocol. The cell media was changed 24 h after transfec-
tion. Cells were generally incubated for 72 h prior to use. For western
blot analysis of CDS, COS-7 cell membranes were used. The COS-7 cells
were sonicated and the lysate was centrifuged at 100,000g for 1 h. at
4 °C to pellet total membranes.
2.5. Western blotting
H9c2 cell were harvested in RIPA buﬀer supplemented with pro-
tease inhibitors (Sigma, P8340). The protein concentration of the ly-
sates was determined using the BCA (bicinchoninic acid) assay and the
proteins (50 μg) were separated by SDS PAGE on 12% acrylamide gels
made in-house. When analysing myc-tagged CDS proteins, Invitrogen
NuPAGE 4–12% Bis-Tris gels had to be used because the myc-tagged
proteins failed to enter the resolving gel in the gels prepared in-house.
After western blotting was completed, Ponceau S staining of the
membrane was carried out as a loading control. (The proﬁle of staining
with Ponceau S before or after performing the western blot is near
identical). The membrane was incubated with Ponceau S solution
(Sigma) for 5 min. The membrane was then washed and imaged under
blue light. For western blot, antibodies were used at the following di-
lutions: CDS1 (1:100); Troponin I (1: 200), PITPNC1 (1:100), COXIV
(1:1000), cytochrome c (1:1000), GRP75 (1:1000), calnexin (1:1000),
PITPα (1:1000), PITPβ (1:1000) and TAMM41 (1:100).
2.6. Measurement of oxygen consumption
Mitochondrial oxygen consumption was analysed using an Oroboros
Oxygraph-2 k as described [35]. Cells were detached using trypsin
(Gibco), harvested and resuspended in HEPES buﬀer (137 mM NaCl,
3.7 mM KCl, 2 mM MgCl2, 1 mM CaCl2, 1 mg/ml BSA and 5.6 mM
Glucose, pH 7.4). Experimental temperature was maintained at 37 °C,
and oxygen concentration readings from the medium were calibrated
according to manufacturer's protocol. 2 ml of H9c2 cells (1–1.6 × 106
cells per ml) were added to the chamber. After reading basal oxygen
consumption measurements (Routine Respiration), oligomycin 2.5 μM
(Sigma) was added to measure Leak respiration. Initial addition of 2 μM
followed by titrations of 0.5 μM of the uncoupler Carbonyl cyanide 4-
(triﬂuoromethoxy)phenylhydrazone (FCCP) (Sigma) was used to induce
and record maximal uncoupled respiration (mETS, electron transport
system, uncoupled). Finally, addition of 2.5 μM antimycin A (Sigma)
allowed the measurement of any non-mitochondrial residual oxygen
consumption (nmt).
2.7. RNA isolation and real time PCR assay
Total RNA was prepared using the Spin Column Total RNA Miniprep
Kit from Qiagen following manufacturer instructions. RNA (1 μg) was
reverse transcribed into cDNA using SuperScript™ II Reverse
Transcriptase and random hexamer primers (Invitrogen). Real-time
quantitative PCR analysis was performed using KAPA SYBR® FAST
qPCR kit Master Mix (KAPABIOSYSTEMS) and primers. (Speciﬁc Rattus
norvegicus primers were designed using the website Primer 3 based on
the NCBI sequences - available on request). Quantitative PCR was
performed using the CFX96 instrument (BioRad) and transcript levels
were determined using the 2−ΔΔCt method and normalized to PGK1
transcript levels [36]. All PCR reactions were performed in triplicate.
2.8. CDS and PI synthase activity
CDP diacylglycerol synthase (CDS) activity on isolated tissue and
cellular samples was determined by measuring the level of incorpora-
tion of [3H]-CTP into CDP-DG using external phosphatidic acid as de-
scribed previously [19]. CDS activity was measured in a 100 μl assay
containing 50 mM Tris-HCl (pH 8), 74 mM KCl, 0.1 mM EGTA, Egg PA
(200 μM), 20 mM MgCl2, 5.1 mM Triton-X100, 0.25 mM DTT, 50 μg
protein, CTP (20 μM) and 2.5 μCi CTP [5′-3H]) (ARC #ART0343). For
the assay, the subcellular fractions were suspended in ice-cold CDS
buﬀer (50 mM Tris-HCL (pH 8.0), 50 mM KCl, 0.2 mM EGTA (ethylene
glycol tetraacetic acid)) and 1/100 v/v protease inhibitor cocktail
(Sigma, P8340). The PA was dried down under nitrogen and re-
suspended in the CDS assay buﬀer comprising of 125 mM Tris-HCl
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(pH 8), 250 mM KCl, 12.75 mM Triton X100, 5 mg/ml BSA and
0.625 mM DTT.
The components of the assay were added in the following order:
48 μl of protein sample (50 μg) (or bovine serum albumin (BSA) as a
control protein), 40 μl PA suspension with 2 μl MgCl2 (1 M) added, and
10 μl of CTP (200 μM) mixed with 2.5 μCi CTP [5′-3H]. The reaction
was incubated for 10 min at 30 °C. (We conﬁrmed that the assay was
linear with respect to protein concentration (0–200 μg) and time
(0–12 min)). It was terminated with 375 μl acidiﬁed chloroform: me-
thanol (1:2) and after phase separation with chloroform and water
(125 μl each), the organic phase was recovered, washed with synthetic
top phase, and the chloroform phase transferred to a scintillation vial.
(The synthetic top phase was a mixture of methanol and water (1:0.9)).
The chloroform was allowed to evaporate prior to counting the radio-
activity in a scintillation counter. PI synthase activity was measured in
a 100 μl assay containing 50 mM Tris-HCL (pH 7.4), 2 mMMnCl2, 50 μg
protein sample, 20 μM unlabelled inositol and 2.5 μCi [3H]myo-inositol
at 37 °C for 15 min. The reaction was conducted at 30 °C for 10 min and
processed as above.
2.9. Subcellular fractionation of rat heart, brain and liver and H9c2 cells
Mitochondria from rat heart were prepared as described [37]. In
brief, two hearts were transferred into TSE buﬀer (200 mM mannitol,
70 mM sucrose, 5 mM Tris-HCl (pH 7.4), and 2 mM EGTA), and per-
fused through the aorta brieﬂy with 25 ml of cold TSE buﬀer to remove
the blood. When treated with protease, the heart was further perfused
with 5 ml of TSE buﬀer containing subtilisin (0.4 mg/ml) (Sigma
P5380). The hearts were trimmed to remove non-ventricular tissue, cut
into small fragments and homogenized with a motorized Potter El-
vehjem glass homogenizer. All centrifugations were carried out at 4 °C.
Nuclei and unbroken cells were pelleted at 850g (3000 rpm) for 5 min.
The supernatant was decanted into a clean tube is referred to as whole
cell lysate (WCL). Protease inhibitors (Cocktail I from Sigma P-8340)
(1:100) were added and an aliquot retained. The mitochondria were
pelleted at 9500g (11,000 rpm) for 15 min (Sorvall) and the super-
natant retained to obtain the microsomes and cytosol. The mitochon-
drial pellet was gently washed with 2 ml of TSE buﬀer to remove a
variable ﬂuﬀy layer. The mitochondrial pellet was resuspended in
40 ml TSE buﬀer and homogenized in a glass homogenizer and re-
covered by centrifugation. This was repeated twice. Where indicated,
the crude mitochondria were further puriﬁed on a Percoll gradient
[38]. The Percoll solution was made by mixing 11.2 ml TSE buﬀer with
4.8 ml Percoll. The crude mitochondria were suspended in 12 ml of TSE
buﬀer. The mitochondria (5 ml) were layered on 8 ml of Percoll solu-
tion and centrifuged in a swingout rotor at 27,000 rpm (95,000g) for
30 min. The mitochondria were recovered as well as the mitochondrial
associated membranes (MAMs). The mitochondria were centrifuged
and retained for subsequent analysis. The MAM fraction and the su-
pernatant containing the cytosol and microsomes were centrifuged at
100,000g for 1 h to recover the MAM fraction, microsomes and cytosol.
Protein concentrations in all the fractions were determined by BCA
assay.
H9c2 cells were pelleted down and resuspended in 1 ml TSE buﬀer
containing 1:100 dilution of protease inhibitors (Sigma). The cells were
sonicated and centrifuged at 330g for 5 min at 4 °C to pellet unbroken
cells. An aliquot of the supernatant (whole cell lysate, WCL) was re-
tained. The remaining supernatant was centrifuged at 8200g for 10 min
at 4 °C to pellet crude mitochondria. This was repeated twice, and the
crude mitochondrial pellets combined, and washed with TSE buﬀer.
The supernatant remaining after crude mitochondria had been sedi-
mented, was centrifuged at 112000g at 4 °C for 1 h to pellet the mi-
crosomes. The crude mitochondrial pellet and the microsomal pellet
was resuspended in CDS buﬀer and sonicated. Protein concentrations in
all the fractions were determined by BCA assay. Cells from three T175
ﬂasks (~2.4 × 107 cells) were used for the fractionation per condition.
2.10. Removal of peripheral proteins with high salt and pH 11 treatment
Mitochondria used for these experiments were frozen at −80 °C in
order to compromise their integrity and thus gain access to the mi-
tochondrial inner membranes. Mitochondria were centrifuged and the
pellets suspended in either 0.2 M sodium bicarbonate (pH 11), 1 M
NaCl (High salt) in CDS buﬀer (50 mM Tris-HCL (pH 8.0), 50 mM KCl,
0.2 mM EGTA) or CDS buﬀer. Each of the buﬀers contained 1:100 di-
lution v/v protease inhibitor cocktail (Sigma, P8340). After incubation
of the sample on a rotating wheel at 4 °C for 60 min, the samples were
recovered by centrifugation. Both the pellet and supernatant were
analysed.
2.11. Measurement of cardiolipin levels
Proliferating H9c2 cell were seeded in 10 cm dishes (6.4 × 104
cells/cm2) and transfected with a mixture of two TAMM41 siRNA
(10 nM) with HiPerFect Transfection Reagent following the manu-
facturer instructions (Qiagen). At the same time, 1 μCi/ml 14C-acetate
(Perkin Elmer) was added to the media to label the lipids to equili-
brium. After 72 h, the cells were recovered by trypsinisation. The cells
were sonicated and centrifuged at 330g for 5 min at 4 °C to pellet un-
broken cells. The supernatant was spun at 8200g for 1 h at 4 °C to pellet
crude mitochondria. The lipids were extracted, and analysed by HPTLC
(Millipore) alongside lipid standards in the solvent mixture CHCl3 (75):
MeOH (45): CH3COOH (3): H2O (1). The plates were then phosphor-
imaged for 3 days (14C) and read on a Fujiﬁlm FLA-2000 before being
analysed with AIDA software. Phosphatidylcholine was used as an in-
ternal standard, and the ratio of cardiolipin to phosphatidylcholine was
used to determine the relative cardiolipin levels.
2.12. Statistical analysis
Statistical analysis was performed by using unpaired two-tailed t-
test, or 1 or 2 way ANOVA with multiple comparisons analysing ex-
perimental data by means of the Prism 6 program (GraphPad software
for Science, San Diego, CA USA).
3. Results
3.1. Diﬀerentiation of H9c2 cells with retinoic acid increases mitochondrial
content, oxygen consumption and CDS1 immunoreactivity
Proliferating H9c2 myoblast cells are relatively undiﬀerentiated
phenotypically but can be induced to diﬀerentiate under reduced serum
conditions. Skeletal or cardiac phenotypes can be induced depending on
whether or not serum reduction is accompanied by daily treatment with
all-trans retinoic acid [39–42]. We induced diﬀerentiation by culturing
H9c2 myoblasts in 1% fetal calf serum in the presence or absence of all-
trans-retinoic acid for 8 days. Diﬀerentiation of H9c2 cells led to a
pronounced change in morphology (Fig. 1A). The morphology of par-
ental cells changed from being spindle to stellate shape with stress ﬁ-
bres to a large elongated shape occasionally multi-nucleated with the
stress ﬁbres being prominent (Fig. 1A). Cardiomyocyte-like diﬀer-
entiation was conﬁrmed by the expression of troponin I (Fig. 1B). Al-
though diﬀerentiation of H9c2 cells with 1% FCS was suﬃcient to in-
duce increases in cytochrome c oxidase subunit IV (COXIV), GRP75
(75 kDa Glucose-regulated protein), and cytochrome c indicating an
increase in mitochondrial biogenesis and/or functionality, retinoic acid
treatment was required for expression of Troponin I. The increase in the
expression of mitochondrial proteins was accompanied by an increase
in oxygen consumption (Fig. 1C and D). Four components of the oxygen
consumption trace are indicated (Fig. 1C), The Routine which measures
the resting consumption, the Leak which is observed after inhibition of
the ATPase with oligomycin, the maximal electron transport system
(mETS) obtained in the presence of the uncoupler, FCCP and ﬁnally the
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non-mitochondrial (nmt) oxygen consumption obtained after addition
of antimycin A (Fig. 1C). Compared to the undiﬀerentiated cells, in the
diﬀerentiated cells there was a robust increase in the Routine, Leak and
mETS after subtraction of the nmt (Fig. 1C and D).
Retinoic acid increases the protein levels of the transcriptional
coactivator PGC-1α (peroxisome proliferator-activated receptor γ
coactivator-1α) [40,42], a master regulator of mitochondrial phos-
pholipid biogenesis [4,5]. It has been recently reported that combined
loss of PGC-1α and β from adult heart resulted in a decrease in cardi-
olipin levels and this was accompanied by reduced mRNA expression of
CDS1 in mice [6]. We therefore examined whether CDS1 protein ex-
pression was increased during diﬀerentiation. A monoclonal antibody
to CDS1 is commercially available and has been previously used for the
detection of CDS1 [43,44]. Using this antibody, a dramatic increase in a
p55 protein running at the expected size for CDS1 (53 kDa) was ob-
served upon diﬀerentiation. The increase was greatest when serum
reduction was accompanied by the presence of retinoic acid (Fig. 1B).
We have previously shown that the PA/PI lipid transporter,
PITPNC1 belonging to the PITP family is enriched in the heart [30] and
we therefore examined its expression following diﬀerentiation of these
cells. Proliferating H9c2 cells and H9c2 cells incubated with 1% FCS did
not show signiﬁcant protein expression of PITPNC1. However, diﬀer-
entiation with retinoic acid showed a pronounced increase in PITPNC1
levels (Fig. 1B). The increase in PITPNC1 was speciﬁc for this transfer
protein, as no increases were observed in two other PITPs, PITPα and
PITPβ (Fig. 1B).
3.2. Localisation of CDS1 immunoreactivity and CDS activity with a
mitochondrial fraction
Having observed an increase in CDS1 and PITPNC1 protein upon
diﬀerentiation, we next examined the subcellular localisation of these
proteins. Diﬀerentiated H9c2 cells were fractionated into microsomes,
crude mitochondria and cytosol. CDS1 immunoreactivity was found
mainly in the mitochondrial fraction as indicated by the presence of
COXIV, GRP75 and cytochrome c (cyto c) (Fig. 2A). The subcellular
fractions were also analysed for CDS activity and mitochondria were
found to be highly enriched (Fig. 2B). The PITP proteins, PITPα and
PITPNC1, localised mainly to the cytosol fraction. Since some calnexin
was also found in the mitochondrial fraction, it suggested that CDS1
could be associated within an ER compartment which was tightly as-
sociated with the mitochondria. Mitochondria normally co-purify with
Fig. 1. Diﬀerentiation of H9c2 cells with
retinoic acid. [A] Morphology examined
by Nomarski optics (upper panels) and
cellular f-actin and nuclei stained with
phalloidin and DAPI respectively (lower
panels). [B] Western blot of cell lysates
(50 μg protein) obtained from pro-
liferating cells (10% FCS) and diﬀer-
entiated cells in either 1% FCS or 1% FCS
with 1 μM retinoic acid (RA). [C] Example
traces of oxygen consumption in pro-
liferating and diﬀerentiated cells (1% FCS
with RA); arrows indicate addition of
drugs, and maximal ETS (electron trans-
port system) indicated by a dotted line
(nmt, non-mitochondrial). [D]
Quantitation of the Routine, Leak and
maximal ETS in proliferating and diﬀer-
entiated cells. The results are averages
from two independent experiments for the
diﬀerentiated cells (1% FCS with RA) and
from three experiments for the pro-
liferating cells. Error bars
denote± S.E.M.
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the sub-region of the ER, referred to as mitochondria-associated en-
doplasmic reticulum membranes (MAMs) [45]. To analyse this further,
we used rat heart due to availability of larger amounts of tissue. Again,
we found that CDS1 immunoreactivity was mainly associated with the
crude mitochondrial fraction (Fig. 2C). The crude mitochondrial frac-
tion was further puriﬁed on Percoll gradients to obtain pure mi-
tochondria and CDS1 immunoreactivity was still present in this fraction
(Fig. 2C). (The entire blot for CDS1 immunoreactivity is shown in
Fig. 2D to demonstrate that the antibody recognises a single band on
the blot.) We also monitored CDS enzyme activity and found that al-
though all fractions contain CDS activity, the highest activity was
present in the pure mitochondrial fraction (Fig. 2E).
In the heart, two populations of mitochondria have been identiﬁed,
mitochondria that lie beneath the sarcolemma and another population
that lie between the myoﬁbrils. To release the inter-ﬁbrillar mi-
tochondria, a protease is often included during mitochondrial pur-
iﬁcation [2]. We therefore puriﬁed the mitochondria in the presence of
the protease. Analysis of the fractions indicated that CDS1 im-
munoreactivity was still found in the mitochondrial fraction (Fig. 2F).
When the fractions were analysed by SDS-PAGE, it was noted that many
of the high molecular weight proteins had disappeared from the cyto-
solic and microsomal fraction but not in the mitochondrial fraction due
Fig. 2. Localisation of CDS1 immunoreactivity and CDS activity to mitochondria.
[A, B] Diﬀerentiated H9c2 cells fractionated and analysed for [A] CDS1 immunoreactivity by Western blot; [B] CDS activity. [C-E] Rat heart fractionated and analysed for [C] CDS1
immunoreactivity and markers, [D] CDS1 immunoreactivity (entire Western blot shown) and [E] CDS activity. [F–H] Rat heart fractionated in the presence of the protease, subtilisin and
analysed for [F] CDS1 immunoreactivity by western blot, [G] CDS activity and [H] PI synthase (PIS) activity. CDS and PIS activity was monitored in triplicate and error bars
denote± S.E.M. COXIV, GRP75 and cyto c are markers for mitochondria, PITPNC1 and PITPα are cytosolic markers and calnexin is a marker for the ER. WCL, whole cell lysate; Micro,
microsomes; C.Mito, crude mitochondria; Cyto, cytosol; P.Mito, pure mitochondria, MAMs, mitochondrial associated membranes; PIS, PI synthase; CDS, CDP-diacylglycerol synthase.
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to the presence of the protease. Nonetheless, the CDS1 immunoreactive
protein and CDS activity were preserved in the mitochondrial fraction
suggesting protection from the protease (Fig. 2F and G). We also
monitored PI synthase activity and found that its activity was also
preserved and was mainly present in the microsomes (Fig. 2H). PI
synthase is a small integral protein of 21 kDa and does not seem to be
aﬀected by the presence of the protease.
To examine whether the localisation of CDS1 immunoreactivity and
enzyme activity is also associated with mitochondria in other tissues,
we tested both rat brain and liver (Fig. 3). Both tissues were fractio-
nated into microsomes, mitochondria and cytosol. The crude mi-
tochondria were further puriﬁed on a Percoll gradient to obtain pure
mitochondria and the MAMs. In both brain and liver, CDS1 im-
munoreactivity was exclusively associated with the pure mitochondrial
fraction (Fig. 3A, B). We also monitored CDS activity and found that the
mitochondria had the highest amount of activity in both brain and liver
(Fig. 3C, D). The presence of PITPNC1 was also monitored and whilst
brain was highly enriched, none was detectable in liver.
3.3. Diﬀerentiation of H9c2 cells did not lead to an increase in CDS1 mRNA
To complement the increase in CDS1 and PITPNC1 im-
munoreactivity following diﬀerentiation, we examined mRNA for
CDS1, CDS2, TAMM41 and PITPNC1. TAMM41 is the mammalian
homologue of the recently identiﬁed CDS enzyme in the yeast, S. cer-
evisiae [26] which is unrelated to CDS1 and 2. No signiﬁcant changes in
CDS1, CDS2 or TAMM41 mRNA was observed (Fig. 4A–C). This result
was surprising considering the dramatic change observed in CDS1 im-
munoreactivity (Fig. 1). In contrast to CDS1 mRNA, an increase in
PITPNC1 mRNA was observed upon diﬀerentiation (Fig. 4D).
3.4. Characterization of the CDS1 antibody
The localisation of CDS1 immunoreactivity in mitochondria was
unexpected as several studies had shown that CDS1 when expressed as a
tagged protein localises at the ER [7,18,19]. The CDS1 monoclonal
antibody used here is a commercial antibody and although used in two
previous studies has not been adequately characterised [43,44]. For
characterization of the antibody, we asked whether the antibody re-
cognises CDS1 and was speciﬁc i.e. it does not cross react with CDS2.
We also used siRNA to knockdown CDS1 to monitor the disappearance
of the CDS1 immunoreactivity.
We expressed Myc-tagged CDS1 and CDS2 in COS-7 cells and after
cell homogenisation, membranes were obtained which were analysed
by western blot with either the CDS1 or the Myc antibody. (We also
examined a commercial CDS2 antibody but it failed to detect over-ex-
pressed CDS2). The CDS1 and the Myc antibody recognised two
common bands, a doublet at ~45 kDa and at ~95 kDa in the Myc-
CDS1-expressing cells (Fig. 5A, marked with a box with dotted lines).
We also observed that the CDS1 antibody recognised an additional band
at around 55 kDa only in the CDS1-over-expressing cells. (We stress that
this immunoreactive band is induced by CDS1 over-expression and is
the same size as the immunoreactive band observed in Figs. 1–3 sug-
gesting that it is likely to be the same cross-reactive protein). The CDS1
antibody did not recognise CDS2 although it was robustly expressed as
conﬁrmed with the Myc antibody (Fig. 5A, right panel). Like CDS1,
CDS2 was detected as two bands, a doublet at ~45 kDa and at
~95 kDa. Expression of the CDS proteins was also conﬁrmed by activity
Fig. 3. CDS1 immunoreactivity and CDS activity localises to mitochondria in rat brain and liver. [A, C] Rat brain and [B, D] liver fractionated and analysed by CDS1 immunoreactivity by
Western blot and for CDS activity. CDS activity was monitored in triplicate and error bars denote S.E.M. WCL, whole cell lysate; Micro, microsomes; C.Mito, crude mitochondria; Cyto,
cytosol; P.Mito, pure mitochondria, MAMs, mitochondrial associated membranes; CDS, CDP-diacylglycerol synthase.
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measurements of the COS-7 membranes (see Fig. 7D). Although CDS2
expression was much greater than CDS1 as observed in the Myc-stained
blot, the CDS activity did not match the expression proﬁle. We attribute
this to the PA substrate used for the assay. We have used egg PA which
is not a good substrate for CDS2 [19]. CDS2 prefers sn-1-stearoyl
(C18:0), sn-2 arachidonyl (C20:4)-PA unlike CDS1 which prefers mono-
saturated fatty acids as used here [19].
An anomaly is immediately apparent; a substantial fraction of the
over-expressed CDS1 and CDS2 runs as a ~95 kDa protein on an SDS-
PAGE gel (theoretical molecular weight is ~53 kDa) suggesting that
some of the CDS proteins remain as a dimer despite the presence of SDS.
This observation concurs with the structure of Cds from the bacterium,
Thermotoga maritama (TmCdsA) which has been recently reported to
form a dimer [17] (Fig. 5B). Our attempts to dissociate the dimer fur-
ther were unsuccessful.
In mitochondria prepared from either heart, liver or brain, the CDS1
antibody recognised a single band running at 55 kDa (Figs. 2D, 3A and
B). These data suggest that the CDS1 antibody, although able to detect
over-expressed CDS1, is very likely detecting a cross-reactive p55 mi-
tochondrial protein. Further support for this suggestion comes from
studies with siRNA. The p55 protein is induced suﬃciently for detection
in whole cell lysates following diﬀerentiation of H9c2 cells (Fig. 1B).
Unfortunately, it was found that siRNA transfection during diﬀer-
entiation frequently led to inhibition of the diﬀerentiation process, as
no increase in Troponin I, PITPNC1 or the p55 protein (detected with
the CDS1 antibody) was apparent (data not shown). The disruption of
the diﬀerentiation process was observed even with a negative control
siRNA and was therefore a non-speciﬁc consequence of transfection
during diﬀerentiation. Thus undiﬀerentiated H9c2 cells had to be used
for the siRNA experiments. Since the immunoreactivity detected with
the CDS1 antibody in undiﬀerentiated H9c2 cell lysates is very weak
(Fig. 1B and Fig. 6A), we prepared mitochondrial fractions to enrich the
signal; the p55 band was now readily detected (Fig. 6A). The siRNA
used to knockdown CDS1 was tested on the mRNA levels (Fig. 6B). RT-
qPCR conﬁrmed that the siRNA reduced CDS1 mRNA with no change in
CDS2 or TAMM41 mRNA (Fig. 6B). Comparison of mitochondria iso-
lated from control and CDS1-siRNA-treated H9c2 cells showed that the
band at 55 kDa was resistant to CDS1 siRNA treatment (Fig. 6C) further
supporting the notion that this is a cross-reactive band detected by the
CDS1 antibody and not CDS1.
3.5. Mitochondrial CDS activity is due to a peripheral protein, TAMM41
Since the CDS1 antibody was only detecting the cross-reactive band
in tissue samples (see Fig. 2D), a diﬀerent approach was taken to ex-
amine whether CDS1 was responsible for the mitochondrial activity. We
ﬁrst over-expressed Myc-tagged CDS1 and CDS2 in COS-7 cells and
prepared total membranes from the lysates. The total membranes were
analysed by Western blot before and after treatment with 0.2 M sodium
bicarbonate (pH 11) to remove peripherally-associated proteins. As
expected, CDS1 and CDS2 remained membrane-associated (compare
Fig. 7A with 7B) as CDS enzymes are integral membrane proteins [17]
(see also Fig. 5B). However, several proteins were removed by this
treatment including the p55 band that is speciﬁcally observed upon
CDS1 over-expression. To check whether CDS1 and CDS2 activity were
aﬀected by exposure to pH 11, we also monitored CDS activity; only a
small decrease in CDS activity was observed in membranes exposed to
pH 11 suggesting that this treatment does not aﬀect CDS1 or 2 activities
(Fig. 7D).
Having conﬁrmed that CDS1 is an integral membrane protein and
Fig. 4. Diﬀerentiation of H9c2 cells does not cause an increase in CDS1 mRNA expression.
H9c2 cells were diﬀerentiated with retinoic acid and samples removed daily to monitor mRNA levels. [A] CDS1 mRNA; [B] CDS2 mRNA; [C] TAMM41 mRNA; [D] PITPNC1 mRNA. Data
from 3 experiments done in triplicate ± S.E.M.
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its activity is unaﬀected when membranes are treated to remove per-
ipheral proteins, we used mitochondria to examine the nature of the
CDS activity as well as the p55 band. We incubated the crude mi-
tochondria with high salt (1 M NaCl in CDS buﬀer) or a sodium bi-
carbonate buﬀer (0.2 M, pH 11). The residual membranes and the re-
sultant supernatant were recovered by centrifugation and the
supernatant concentrated and analysed for CDS1 immunoreactivity.
The p55 protein was removed from the membranes and recovered in
the supernatant indicating that it is a peripheral membrane protein
(Fig. 7E). These data conclusively demonstrates that the CDS1 anti-
body, although able to detect the over-expressed CDS1 protein by
western blot, also recognises an additional peripheral protein that is
exclusively localised in mitochondria.
To examine the nature of the mitochondrial CDS activity, the mi-
tochondria stripped of peripheral proteins were assessed for CDS ac-
tivity. The mitochondrial activity was partially lost after treatment with
NaCl or near-completely lost after treatment with sodium bicarbonate
(Fig. 7F) excluding this activity to be due to CDS1 or CDS2. We
therefore surmised that the CDS activity present in mitochondria could
potentially be due to the mammalian homologue of the yeast enzyme,
Tam41 (also known as MMP37, mitochondrial matrix protein of 37 kDa
[46,47]). To test this, H9c2 cells were treated with TAMM41 siRNA. We
ﬁrst conﬁrmed that the siRNA was eﬀective in reducing the expression
of TAMM41 mRNA (Fig. 8A). We have used an anti-TAMM41 antibody
from ATLAS antibodies (HPA036834) and ﬁrst validated the antibody.
Crude mitochondria prepared from H9c2 cells had to be used to enrich
the antigen, and a band of the appropriate molecular weight was ob-
served. This band was reduced in the TAMM41 knockdown crude mi-
tochondria (Fig. 8B and C).
H9c2 cells were fractionated to separate mitochondria from the
microsomes and fractions analysed for CDS activity. A signiﬁcant re-
duction was observed in the mitochondrial fraction prepared from cells
Fig. 5. CDS1 antibody recognises over-expressed CDS1 but not over-expressed CDS2.
[A] Myc-tagged CDS1 and CDS2 were expressed in COS-7 cells and membranes obtained after centrifugation. Membranes (25 μg protein per lane) probed with antibodies to CDS1 (left
panel) and Myc (right panel). The boxed region highlights the over-expressed proteins. CDS proteins run as monomers (~45 kDa) and as dimers (~95 kDa). The CDS1 antibody (Abcam)
also recognises a p55 protein in the CDS1-over-expressing cells. [B] Topological organisation of the CDS enzymes, CDS1, CDS2 and TmCdsA based on the structure of TmCdsA, and the
structurally unrelated CDS enzyme, TAMM41. The transmembrane domains of CDS1 and CDS2 are shown in coloured boxes. Blue boxes, N-terminal domain, green boxes, middle domain
which is the dimerization interface and the orange boxes which is the highly-conserved C-terminal domain. Also shown is the three dimensional structure of TmCdsA which forms a dimer;
the monomers are coloured red or yellow. Cartoon representation of CDS1 and CDS2 based on TmCdsA dimer. TAMM41 (NP_001271330.1) is shown as a peripheral membrane protein
containing the MMP37 domain (MMP37, mitochondrial matrix proteins of 37 kDa; PFAM: 09139) [46].
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treated with TAMM41 siRNA (Fig. 8D). These data conﬁrm that the
activity observed in mitochondria is due to TAMM41. To assess whether
knockdown of TAMM41 resulted in changes in cardiolipin level, H9c2
cells were grown in 14C-acetate for 72 h to label the lipids to near
equilibrium. Mitochondria were prepared from control and knockdown
cells and analysed by TLC. A signiﬁcant decrease in cardiolipin was
observed (Fig. 8E).
Finally, we examined whether the knockdown of TAMM41 had any
impact on respiration as cardiolipin has numerous roles in the stabili-
sation of the COX complexes and other respiratory roles [48]. Fig. 8F
shows an example trace of control and TAMM41 knockdown cells and
Fig. 8G shows the oxygen ﬂow per million cells across 3 experiments.
Over the course of the experiments there were variations in the routine
reading – the basal oxygen consumption of the cells. Although there
was no statistical signiﬁcance observed in the three combined experi-
ments, throughout each experiment there was a downward trend; the
TAMM41 knockdown cells had a lower basal level of oxygen con-
sumption (Negative siRNA 69.3 ± 6.4 pmol/(s*million cells);
TAMM41 siRNA, 57.8 ± 5.1 (pmol/s*million cells)). When looking at
the maximal capacity of the electron transport chain (mETS), the mETS
of the TAMM41 knockdown had signiﬁcantly decreased from
212.6 ± 7.2 to 180.3 ± 9.8 pmol/(s*million cells) (p < 0.01).
Treatment of mitochondrial membranes with pH 11 buﬀer led to a
substantial loss of CDS activity (Fig. 7F). We therefore wanted to ex-
amine whether the activity could be recovered in the supernatant. Rat
brain mitochondria were incubated with CDS buﬀer (50 mM Tris-HCL
(pH 8.0), 50 mM KCl, 0.2 mM EGTA) or with 0.2 M sodium bicarbonate
(pH 11). The supernatants were recovered and concentrated and ex-
amined for CDS activity alongside the mitochondrial pellets (Fig. 9A).
As expected the mitochondria recovered after pH 11 treatment had lost
a substantial amount of activity. From three independent experiments,
the residual activity left was between 5 and 15%. A small amount of
activity was recovered in the control supernatant but none in the pH 11
supernatant (Fig. 9A). (The supernatants were concentrated and buﬀer
exchanged before analysis). This result suggested that prior exposure to
pH 11 irreversibly inactivates TAMM41 activity.
Since 1 M salt treatment of mitochondria also shows some reduction
in CDS activity (Fig. 7F), we examined whether CDS activity could be
recovered from the supernatant after treatment with 1 M NaCl. We ﬁrst
used the antibody to demonstrate that the TAMM41 protein could be
removed from the mitochondria with either salt treatment or with
pH 11. As expected salt treatment removed less protein compared to
pH 11 treatment. Moreover, we recovered TAMM41 protein in the
pH 11 supernatant (Fig. 9B).
Crude mitochondria were incubated with high salt or CDS buﬀer.
The supernatant and the recovered pellets were examined for TAMM41
immunoreactivity (Fig. 9C). We noted that control supernatant con-
tained some TAMM41 immunoreactivity which increased substantially
in the supernatant obtained after salt treatment. The supernatants de-
rived after treatment were concentrated and buﬀer exchanged to re-
move the high salt. Measurement of activity in these two supernatants
showed that the salt extract had greater activity compared to control
(Fig. 9D).
3.6. CDS1 and CDS2 make a minor contribution to crude mitochondrial
CDS activity
In TAMM41 knockdown H9c2 cells, a substantial fraction of CDS
activity was still present in mitochondria (Fig. 8D); this could be ac-
counted for by incomplete knockdown (Fig. 8B and C). However, some
CDS activity is retained after treatment of mitochondria with pH 11
which has to be contributed by CDS1 or CDS2. To examine this con-
tribution, we used siRNA to knockdown CDS1 and CDS2 mRNA
(Fig. 10A and C). The H9c2 cells from control and siRNA treated cells
were fractionated and CDS activity monitored (Fig. 10B and D). We
observed a slight decrease in mitochondrial CDS activity in both CDS1
and CDS2 knockdown cells. Since crude mitochondria were used, we
also monitored the presence of ER membranes in the crude mitochon-
dria. As expected, the crude mitochondria contained signiﬁcant ER
membranes (Fig. 10E).
4. Discussion
4.1. TAMM41 accounts for the mitochondrial CDS activity
The most important ﬁnding of this study is the identiﬁcation of the
mitochondrial CDS activity as TAMM41 and not CDS1. Previous studies
had indicated that CDS activity was associated with mitochondria as
well as with microsomes and yet expression of the two CDS proteins
was normally found in the ER [7,19], leaving open the question of the
identity of the mitochondrial CDS activity. Fractionation of mitochon-
dria from H9c2 cells and from tissues including rat heart, liver and
brain indicated that puriﬁed mitochondria are highly enriched in CDS
activity. Although using a commercial antibody suggested that this was
due to CDS1, we provide compelling evidence that this activity is not
due to CDS1 but due to a peripheral protein, TAMM41. Recent studies
in yeast have identiﬁed a new enzyme, Tam41 that possesses CDS ac-
tivity. Tam41 is a peripheral membrane protein that localises in the
inner mitochondrial matrix where it is involved in cardiolipin synthesis
[26]. Tam41 and the yeast Cds1 have diﬀerent evolutionary origins and
are not related by sequence although both possess CDS activity [26]
(See Fig. 5B). A mammalian homologue of Tam41, TAMM41 (alias
C3orf31) is a protein-coding gene present in the NCBI database and in
the human MitoCarta2 database. It comprises of 337 amino acid re-
sidues with a calculated molecular weight of 35 kDa and possesses a
Fig. 6. Knockdown of CDS1 with siRNA does not lead to a reduction in the p55 band.
[A] Detection of the p55 band with the CDS1 antibody in undiﬀerentiated H9c2 cells is
only possible when mitochondrial fractions are prepared. [B] Validation of CDS1 siRNA.
A decrease in CDS1 mRNA (P < 0.0001, n = 6,± S.E.M.) but not CDS2 or TAMM41 is
observed when undiﬀerentiated H9c2 cells were treated with CDS1 siRNA. [C]
Mitochondrial fractions prepared from control, negative siRNA-treated and CDS1 siRNA-
treated H9c2 cells were analysed for CDS1 immunoreactivity by Western blot. WCL,
whole cell lysate; C.Mito, crude mitochondria; Micro, microsomes.
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mitochondrial targeting sequence. Mitochondrial CDS activity (Fig. 8D)
and cardiolipin levels (Fig. 8E) were partially reduced when H9c2 cells
were treated with TAMM41 siRNA. Cardiolipin is an essential lipid for
the activity of a number of key mitochondrial enzymes involved in
cellular energy metabolism. Consequently, a modest decrease in basal
oxygen consumption as well as in the maximal capacity of the electron
transport chain was observed (Fig. 8F, G).
CDS activity is only partially reduced in TAMM41 knockdown mi-
tochondria. This reduction is probably partial due to incomplete
knockdown of TAMM41. Alternatively, CDS1 or CDS2 could contribute
to mitochondrial activity. Our data excludes this possibility; the main
evidence comes from the observation that only 5–15% of CDS activity
remains in mitochondria after TAMM41 is irreversibly inactivated by
pH 11 exposure. To identify whether the residual activity is due to
CDS1 or CDS2, both CDS enzymes were knocked-down by siRNA.
Knockdown of CDS2, but not CDS1, lead to a small decrease in crude
mitochondrial CDS activity (Fig. 10B and D). However, the crude mi-
tochondria were found to be associated with ER (Fig. 10E), and
therefore the CDS2 activity is likely derived from that compartment. We
conclude that the CDS activity in mitochondria is exclusively due to
TAMM41 and the ER membranes associated with mitochondria are
responsible for the residual CDS activity.
4.2. The CDS1 antibody recognises a cross-reactive p55 protein
In this study, we used a commercial antibody to examine for CDS1
protein previously used in two other publications [43,44]. In these
publications as well as our study, this monoclonal antibody recognised
a p55 protein. Indeed as shown in Fig. 2D, the antibody only recognises
a single band on the gel when rat heart, liver or brain fractions were
analysed. Because of our unexpected results indicating that CDS1 was a
mitochondrial protein, we characterised the antibody. It appears to be
normal practice that commercial antibodies are often used without any
further authentication. We validated the antibody using over-expressed
CDS1 and found that the antibody did recognise CDS1 but not CDS2 by
western blot (Fig. 5A). However, the antibody only detects a cross-re-
active p55 mitochondrial protein in heart, liver or brain. In COS-7 cells,
the antibody also detects a p55 protein which is induced when CDS1 is
over-expressed (Figs. 5A and 7A). In H9c2 cells the protein is present at
low levels and is upregulated following diﬀerentiation to either skeletal
muscle or cardiomyocytes (Fig. 1B). These data suggest that CDS1 over-
expression does regulate mitochondrial dynamics by upregulating a
mitochondrial protein.
Our attempts to identify this cross-reactive protein have not been
successful. We partially puriﬁed the protein from mitochondria and the
Fig. 7. Mitochondrial CDS activity is due to a peripheral membrane protein.
[A, B] Total membranes (50 μg protein) prepared from COS-7 cells expressing either Myc-CDS1 or Myc-CDS2 were analysed by western blot [A] before and [B] after treatment with 0.2 M
sodium bicarbonate (pH 11). [C] Loading Control: Ponceau S stain of blots in [A]. [D] CDS activity of COS-7 cell total membranes (50 μg protein) before and after treatment with sodium
bicarbonate. [E, F] Mitochondria puriﬁed from rat brain were incubated with high salt (1 M NaCl) or with sodium bicarbonate to remove peripheral proteins. [E] The residual
mitochondrial membranes and supernatant were analysed by Western blot with CDS1 and COXIV antibody. [F] The membranes were analysed for CDS activity.
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p55 protein band was analysed by Mass Spectroscopy. Although several
promising hits were obtained including thioredoxin reductase 2
(TXNRD2), none of these hits were recognised by the CDS1 antibody.
Hence, we were unable to conﬁrm the identity of the p55 protein. The
identity of this protein would be interesting for the following reasons:
Firstly, diﬀerentiation of H9c2 cells causes a dramatic increase in its
expression. Secondly, this antibody has been used in two other studies
and we speculate that the protein identiﬁed in these two studies was not
CDS1 but the p55 protein identiﬁed here. In one of these studies, the
panel of non-small cell lung cancer (NSCLC) cell lines were examined
for genes that were up-regulated by the transcription factor, ZEB1.
CDS1 mRNA was found to be lower in cells that had high levels of ZEB1
mRNA and vice versa. These results were validated by showing that
over-expression of ZEB1 in H358 cells caused a considerable decrease in
Fig. 8. Mitochondrial CDS activity is due to TAMM41 and its knockdown reduces oxygen consumption. [A] Knockdown of TAMM1 mRNA by siRNA in H9c2 cells (n = 3, unpaired two-
tailed t-test). [B] Western blot showing knockdown of TAMM41 protein in the crude mitochondrial fractions from TAMM41 knockdown cells. Loading control: Ponceau S stain of the blot.
Crude mitochondria were prepared from H9c2 cells treated with control or TAMM41 siRNA. Representative blot of two independent crude mitochondrial fractions. [C] Quantiﬁcation of
TAMM41 protein in crude mitochondria from 4 independent fractionations (n = 4, unpaired two-tailed t-test). [D] CDS activity after TAMM41 knockdown in H9c2 subcellular fractions.
Results are from two independent experiments done in triplicate (n = 6, two-way ANOVA with multiple comparisons). The average activity in control whole cell lysates from diﬀerent
experiments was in the range of 2–6 pmol/mg/min. WCL, whole cell lysate; C.Mito, crude mitochondria; Micro, microsomes; [E] Cardiolipin levels in crude mitochondria prepared from
control and TAMM41 siRNA-treated H9c2 cells. H9c2 cells were labelled to near equilibrium with 14C-acetate for 72 h and lipids extracted from crude mitochondrial fractions and
analysed by TLC. Results are from 3 independent experiments done in duplicate or triplicate (n = 8, unpaired two-tailed t-test). [F] Example trace of oxygen consumption in control and
TAMM41 knockdown H9c2 cells; arrows indicate addition of drugs and maximal ETS (electron transport system) shown by dotted line. nmt, non-mitochondrial; O, oligomycin; F, FCCP;
A, antimycin A. [G] Quantitation of the Routine, Leak and maximal ETS in control and TAMM41-knockdown cells. The results are averages from three independent experiments; two way
ANOVA with multiple comparisons Error bars denote± S.E.M.
N.J. Blunsom et al. BBA - Molecular and Cell Biology of Lipids 1863 (2018) 284–298
295
CDS1 mRNA whilst siRNA for ZEB1 (and ZEB2) led to a considerable
increase in CDS1 mRNA. In addition to monitoring mRNA, they used
the same commercial monoclonal CDS1 antibody used here to conﬁrm
their data. They showed that the antibody recognised a p55 protein; we
would suggest that the immunoreactive band is unlikely to be CDS1 but
a mitochondrial protein [43]. Thus ZEB1 appears to downregulate not
only CDS1 (shown by mRNA) but also a mitochondrial protein (shown
by western blot). The ZEB family of zinc ﬁnger transcription factors are
essential players during normal embryonic development and one
characteristic is that they induce epithelial to mesenchymal transition
(EMT), a process that reorganizes epithelial cells to become migratory
mesenchymal cells. The relevance of ZEB1 and mitochondria might be
an interesting topic for exploration. This study shows a relationship
between CDS1 mRNA and the p55 band; a decrease in CDS1 mRNA
correlated with the decrease in the p55 band. In our study we observe
the converse; over-expression of CDS1 increased the expression of the
p55 protein (Figs. 5A and 7A). Thus there appears to be a strong link
between CDS1 and the p55 mitochondrial protein.
4.3. Criteria for antibody characterization
Since commercial antibodies are the most commonly used tools in
the biosciences, it is important that all antibodies should be validated
prior to use. The use of uncharacterised antibodies in the scientiﬁc
literature is very common and this may compromise these studies. This
issue has been highlighted recently [49–51] and here we provide an
example of a previously-used commercial antibody that predominantly
recognises a cross-reactive protein rather than the target protein. We
suggest the following minimum criteria that should be applied routinely
for validation of new antibodies. These criteria should be applied for
every new technique that the antibody is used for. Thus an antibody
validated for western blot should be independently validated if used for
immunoﬂuorescence. Our three criteria for western blot are: [1] the
antibody should recognise over-expressed protein or recombinant pro-
tein; [2] the antibody should recognise the protein of the expected size;
[3] knockout of the protein by siRNA or CRISPR/Cas9 to demonstrate
loss of signal.
4.4. Diﬀerentiation of H9c2 cells
H9c2 cells are increasingly used as an alternative to cardiomyocytes
thus reducing the use of animals. Previous studies have shown that
during diﬀerentiation of H9c2 cells with retinoic acid, the cardiac L-
type voltage-dependent calcium channels is induced as evidenced by
expression of the pore-forming α1C subunit as well as cardiac troponin T
and troponin I [39,42]. A recent study performed a transcriptional
analysis of the H9c2 cell line in the proliferating and retinoic acid-
diﬀerentiated state and conﬁrmed altered gene expression including
increases in genes associated with mitochondrial energy production
[42]. Our results extend this dataset; not only do we demonstrate in-
creases in mitochondrial proteins and a cardiac marker, troponin I as
expected, we show a speciﬁc increase in the expression of PITPNC1,
both at the mRNA and protein level (Figs. 1B and 4D). Adult cardiac
myocytes exhibit tissue-speciﬁc expression of many proteins and we can
now include PITPNC1 as one of them. Our previous studies had iden-
tiﬁed adult heart as the main tissue that expressed PITPNC1 [30] thus it
was initially surprising that H9c2 cells showed little expression of
PITPNC1. H9c2 cells proliferate in the presence of serum (10%) but if
serum is withdrawn the cells transdiﬀerentiate to a skeletal phenotype.
However, if serum withdrawal is accompanied by daily treatment with
all-trans-retinoic acid, a cardiac phenotype is observed. Expression of
PITPNC1 is substantially increased when the cells diﬀerentiate towards
a mature cardiac phenotype.
Diﬀerentiated H9c2 cells remodel their metabolism and instead of
relying on glycolysis, the cells become more dependent on oxidative
metabolism [41]. This change in energy metabolism requires increased
expression of mitochondrial proteins and in H9c2 cells treatment with
retinoic acid was found to increase the expression of several mi-
tochondrial markers including GRP75, COXIV and cytochrome C
(Fig. 1). The transcriptional co-activator, PGC-1α acts as a master
Fig. 9. TAMM41 protein is released from the mi-
tochondria after treatment with high salt and its ac-
tivity is recovered in the supernatant. [A] Liver mi-
tochondria were incubated with CDS buﬀer (50 mM
Tris-HCL (pH 8.0), 50 mM KCl, 0.2 mM EGTA) or with
0.2 M sodium bicarbonate (pH 11). The supernatants
were recovered, concentrated and buﬀer exchanged.
CDS activity was monitored in the pellets and the su-
pernatants. [B] Western blot of crude mitochondria
treated with 1 M NaCl and pH 11 buﬀer and pH 11 su-
pernatant. [C] Liver mitochondria were incubated with
control buﬀer or control buﬀer supplemented with 1 M
sodium chloride for 1 h. The mitochondrial pellets and
the respective supernatants were Western blotted with
TAMM41 antibody. P., pellet; SN, supernatant. [D] The
supernatant from [C] was concentrated, buﬀer ex-
changed and CDS activity was assessed. Data from two
experiments performed in triplicate± S.E.M.
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regulator of energy metabolism and mitochondrial biogenesis and dif-
ferentiation of H9c2 cells with retinoic acid causes a substantial in-
crease in PGC-1α expression [40,42]. Our results conﬁrm that retinoic
acid treatment causes the H9c2 cells towards a cardiac phenotype with
diﬀerentiation-associated changes in mitochondrial biogenesis [40] and
show that PITPNC1 is a new and novel biochemical marker for the
diﬀerentiated state. Moreover, PITPNC1 was also found highly enriched
in the brain, but absent in liver. This suggests that PITPNC1 has tissue-
speciﬁc functions rather than a house-keeping function. Its investiga-
tion in cultured H9c2 cells is hampered because knockdown of proteins
during diﬀerentiation is technically a problem. Recent work has iden-
tiﬁed that PITPNC1 is over-expressed in multiple cancer types and fa-
cilitates Golgi extension and vesicular secretion of pro-tumour factors in
these cancer cells. PITPNC1 was found to associate with RAB1B and
aiding the recruitment of GOLPH3 to the Golgi [52].
The majority of studies utilising H9c2 cells as a model for cardio-
myocytes do not diﬀerentiate the cells [53,54]. We would suggest that
this could distort the results as it is noted that H9c2 cells are increas-
ingly used to study the eﬀects, mechanisms, and therapeutic interven-
tions for hypoxia/re‑oxygenation, autophagy, hypertrophy, insulin
resistance, apoptosis, endoplasmic reticulum–mitochondria interactions
and cellular signalling studies [54].
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